PlainPharmaWatch

CMS Open Payments · Program Year 2024

Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc reported $2,796,389.90 in payments to 26,764 physicians and teaching hospitals across 27,568 transactions.

See the rankings → How this is sourced
$2.8M
Total payments
27,568
Transactions
26,764
Recipients
#379
of 1,925 companies

Kiniksa Pharmaceuticals International, plc reported $2,796,389.90 in payments to 26,764 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #379 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $104.48 per recipient across 8 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Kiniksa Pharmaceuticals International, plc pairs top-quartile payment volume with an unusually diversified payment pattern across a wide recipient base.

#379
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
8
payment categories

How Kiniksa Pharmaceuticals International, plc ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Kiniksa Pharmaceuticals International, plc's total vs. every reporting company

CMS Open Payments, Program Year 2024

$2,796,390 Top 20% higher than 80% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). This entry sits in this band. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc ranks #379 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $2,796,389.90 across 27,568 transactions to 26,764 physicians and teaching hospitals - $101.44 per transaction and $104.48 per recipient on average.

26,095 transactions worth $626.1K make "Food and Beverage" the top general-payment category in the 8-category breakdown below, 22.4% of the reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Kiniksa Pharmaceuticals International, plc made 8 types of general payments. "Food and Beverage" is the largest category at $626.1K, 22.4% of the company's reported total.

How Kiniksa Pharmaceuticals International, plc divides its payments

Ranked by total dollars reported per category

1. Food and Beverage$626.1K2. Compensation for Services…$574.2K3. Space Rental or Facility …$255.3K4. Royalty or License$126.8K5. Travel and Lodging$88.6K6. Consulting Fee$52.3K7. Education$11.5K8. Charitable Contribution$10.0K
Payment Type Amount Transactions
Food and Beverage $626.1K 26,095
Compensation for Services Other Than Consulting $574.2K 242
Space Rental or Facility Fees $255.3K 43
Royalty or License $126.8K 10
Travel and Lodging $88.6K 337
Consulting Fee $52.3K 32
Education $11.5K 4
Charitable Contribution $10.0K 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $363,342.67 (20.8%) of $1,744,692.94 in this company's General Payments records across 12,258 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Kiniksa Pharmaceuticals International, plc

The five named recipients with the highest reported General Payments from this company

Beth Israel Deaconess Medica…$126.8KJohn Ryan$74.2KRobert Biederman$58.8KDavid Homan$55.2KJohn Isaac$48.4K
  1. 1

    Beth Israel Deaconess Medical Center

    $126,759.79 across 10 reported transactions

  2. 2

    John Ryan

    $74,175.88 across 82 reported transactions

  3. 3

    Robert Biederman

    $58,792.74 across 58 reported transactions

  4. 4

    David Homan

    $55,187.61 across 68 reported transactions

  5. 5

    John Isaac

    $48,426.65 across 57 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $101.44. Average per recipient: $104.48.

Total Amount

$2,796,389.90

Avg per Transaction

$101.44

Avg per Recipient

$104.48

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Kiniksa Pharmaceuticals International, plc Share

0.0%

#379 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Kiniksa Pharmaceuticals International, plc

Olympus America Inc.

$2.8M 7,547 recipients

Peter Brasseler Holdings, LLC

$2.8M 553 recipients

Skeletal Dynamics Inc

$2.8M 1,938 recipients

Cochlear Americas

$2.8M 1,888 recipients

Philadelphia Medical Management Company LLC

$2.8M 4 recipients

Orthalign Inc

$2.8M 713 recipients

Frequently Asked Questions

How much did Kiniksa Pharmaceuticals International, plc pay to physicians and hospitals in 2024? ▾
Kiniksa Pharmaceuticals International, plc made $2,796,389.90 in payments to physicians and hospitals in Program Year 2024, across 27,568 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Kiniksa Pharmaceuticals International, plc? ▾
Averaging $104.48 per recipient, Kiniksa Pharmaceuticals International, plc's 2024 payments reached 26,764 physicians and teaching hospitals.
What types of payments did Kiniksa Pharmaceuticals International, plc make? ▾
Kiniksa Pharmaceuticals International, plc made 8 different types of general payments (consulting, meals, travel, and similar categories). The largest general-payment category was "Food and Beverage" at $626.1K, representing 22.4% of the company's reported total.
How does Kiniksa Pharmaceuticals International, plc rank among pharmaceutical companies? ▾
Kiniksa Pharmaceuticals International, plc ranks #379 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from Kiniksa Pharmaceuticals International, plc? ▾
Kiniksa Pharmaceuticals International, plc's 27,568 transactions to 26,764 recipients in 2024 averaged $101.44 per transaction.
Where does the payment data for Kiniksa Pharmaceuticals International, plc come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Kiniksa Pharmaceuticals International, plc's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.